1. Home
  2. CPBI vs LUNG Comparison

CPBI vs LUNG Comparison

Compare CPBI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$20.00

Market Cap

83.2M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.88

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CPBI
LUNG
Founded
2023
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
97.1M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
CPBI
LUNG
Price
$20.00
$1.88
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
4.8K
★ 262.1K
Earning Date
11-18-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 9.38
7.64
EPS
★ 0.39
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
$51.26
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$15.56
$1.13
52 Week High
$21.83
$2.89

Technical Indicators

Market Signals
Indicator
CPBI
LUNG
Relative Strength Index (RSI) 49.49 41.98
Support Level $19.73 $1.20
Resistance Level $20.74 $2.12
Average True Range (ATR) 0.23 0.10
MACD -0.09 -0.01
Stochastic Oscillator 43.10 27.19

Price Performance

Historical Comparison
CPBI
LUNG

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: